60 Degrees Reports Negative PCR Results in All Five Completed Babesiosis Study Patients
60 Degrees Pharmaceuticals announced clinical improvement and negative conventional PCR results in all five patients who completed treatment in its expanded access babesiosis study, with four of five also NAT-negative on a highly sensitive post-treatment test. The company says the study remains open pending potential discussions with the FDA, and the filing reports no financial results, so the update is clinical and regulatory rather than a measure of current business performance.
Key points
- All five completed patients were much or very much improved and tested negative on conventional PCR
- Four of five completed patients (80%) were nonreactive on post-treatment blood-donor NAT testing
- Two additional patients remain on treatment, bringing total enrollment to seven
- Tafenoquine is not FDA-approved for babesiosis; the hospital-setting randomized study is expected to unblind in January 2027
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.